These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37003027)

  • 41. Assessing the introduction of universal rotavirus vaccination in the Netherlands.
    Zomer TP; van Duynhoven YT; Mangen MJ; van der Maas NA; Vennema H; Boot H; de Melker HE
    Vaccine; 2008 Jul; 26(29-30):3757-64. PubMed ID: 18514975
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-benefit analysis of rotavirus vaccine included in the national immunization program in China.
    Chen S; Gao S; Li J; Li J; Duan ZJ
    Vaccine; 2023 Jan; 41(2):547-554. PubMed ID: 36503856
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anticipating rotavirus vaccines: hospital-based surveillance for rotavirus diarrhea and estimates of disease burden in Bangladesh.
    Unicomb LE; Kilgore PE; Faruque SG; Hamadani JD; Fuchs GJ; Albert MJ; Glass RI
    Pediatr Infect Dis J; 1997 Oct; 16(10):947-51. PubMed ID: 9380469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness analysis of rotavirus vaccination among Libyan children using a simple economic model.
    Alkoshi S; Maimaiti N; Dahlui M
    Libyan J Med; 2014; 9(1):26236. PubMed ID: 25499622
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hospital-based Surveillance for Rotavirus Gastroenteritis Among Young Children in Bangladesh: Defining the Potential Impact of a Rotavirus Vaccine Program.
    Satter SM; Gastanaduy PA; Islam K; Rahman M; Rahman M; Luby SP; Heffelfinger JD; Parashar UD; Gurley ES
    Pediatr Infect Dis J; 2017 Feb; 36(2):168-172. PubMed ID: 27798545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An economic analysis of rotavirus vaccination in Italy.
    Giammanco MD; Coniglio MA; Pignato S; Giammanco G
    Vaccine; 2009 Jun; 27(29):3904-11. PubMed ID: 19446934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales.
    Atkins KE; Shim E; Carroll S; Quilici S; Galvani AP
    Vaccine; 2012 Nov; 30(48):6766-76. PubMed ID: 23000223
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic impact of a rotavirus vaccination program in Mexico.
    Constenla D; Velázquez FR; Rheingans RD; Antil L; Cervantes Y
    Rev Panam Salud Publica; 2009 Jun; 25(6):481-90. PubMed ID: 19695142
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China.
    Liu N; Yen C; Fang ZY; Tate JE; Jiang B; Parashar UD; Zeng G; Duan ZJ
    Vaccine; 2012 Nov; 30(48):6940-5. PubMed ID: 22705174
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Health and economic impact of rotavirus vaccination in GAVI-eligible countries.
    Kim SY; Sweet S; Slichter D; Goldie SJ
    BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dynamic modeling of cost-effectiveness of rotavirus vaccination, Kazakhstan.
    Freiesleben de Blasio B; Flem E; Latipov R; Kuatbaeva A; Kristiansen IS
    Emerg Infect Dis; 2014 Jan; 20(1):29-37. PubMed ID: 24378188
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness analysis of vaccination against rotavirus with RIX4414 in France.
    Standaert B; Parez N; Tehard B; Colin X; Detournay B
    Appl Health Econ Health Policy; 2008; 6(4):199-216. PubMed ID: 19382820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Introducing rotavirus vaccine in eight sub-Saharan African countries: a cost-benefit analysis.
    Okafor CE; Ekwunife OI
    Lancet Glob Health; 2021 Aug; 9(8):e1088-e1100. PubMed ID: 34297961
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia.
    Reyes JF; Wood JG; Beutels P; Macartney K; McIntyre P; Menzies R; Mealing N; Newall AT
    Vaccine; 2017 Jan; 35(2):345-352. PubMed ID: 27916411
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rotavirus Vaccination Likely to Be Cost Saving to Society in the United States.
    Newall AT; Leong RN; Reyes JF; Curns AT; Rudd J; Tate J; Macartney K; Parashar U
    Clin Infect Dis; 2021 Oct; 73(8):1424-1430. PubMed ID: 34038527
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potential cost-effectiveness of a rotavirus immunization program in rural China.
    Wang XY; Riewpaiboon A; von Seidlein L; Chen XB; Kilgore PE; Ma JC; Qi SX; Zhang ZY; Hao ZY; Chen JC; Xu ZY
    Clin Infect Dis; 2009 Oct; 49(8):1202-10. PubMed ID: 19739973
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cost-effectiveness of a pentavalent rotavirus vaccine in Japan.
    Itzler R; O'Brien MA; Yamabe K; Abe M; Dhankhar P
    J Med Econ; 2013 Oct; 16(10):1216-27. PubMed ID: 23919721
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A cost-effectiveness analysis on universal infant rotavirus vaccination strategy in China].
    Sun SL; Gao YQ; Yin J; Zhuang GH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Feb; 37(2):238-42. PubMed ID: 26917523
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda.
    Tate JE; Kisakye A; Mugyenyi P; Kizza D; Odiit A; Braka F
    Vaccine; 2011 Apr; 29(17):3329-34. PubMed ID: 21241733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.